GU Cancers 2020 | Immunotherapy with radiotherapy in RCC: is there a benefit?

Name: Immunotherapy with radiotherapy in RCC: is there a benefit?
Uploaded: 2020-02-15T10:52:50Z
Description: Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the results of the RADVAX trial (NCT03065179) combining immune checkpoint inhibition with stereotactic radiation in metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Thomas Powles • 15 Feb 2020

GU Cancers 2020

Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab

RADVAX

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the results of the RADVAX trial (NCT03065179) combining immune checkpoint inhibition with stereotactic radiation in metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.